Celldex Therapeutics market cap is $36 m, and annual revenue was $9.54 m in FY 2018

Celldex Therapeutics Net income (Q2, 2019)-11.8 M

Celldex Therapeutics EBIT (Q2, 2019)-12.3 M

Celldex Therapeutics Cash, 30-Jun-201919.7 M

Celldex Therapeutics EV18.8 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|

## Revenue | 4.1m | 3.6m | 5.5m | 6.8m | 12.7m | 9.5m | |

| (13%) | 53% | 24% | ||||

## R&D expense | 67.4m | 100.2m | 102.7m | 96.2m | 66.4m | ||

## General and administrative expense | 14.8m | 33.8m | 36.0m | 25.0m | 19.3m | ||

## Operating expense total | 85.6m | 135.0m | 139.7m | 134.3m | 166.0m | ||

## EBIT | (81.4m) | (122.4m) | (129.5m) | (132.9m) | (121.5m) | (156.4m) | |

| (1981%) | (3414%) | (2364%) | (1959%) | (954%) | (1640%) | |

## Interest expense | 927.0k | ||||||

## Income tax expense | 24.3m | 765.0k | |||||

## Net Income | (81.5m) | (118.1m) | (127.2m) | (128.5m) | (128.5m) | (93.0m) | (151.2m) |

- Source: SEC Filings

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 980.0k | 416.0k | 592.0k | 1.1m | 2.2m | 1.0m | 1.3m | 1.4m | 2.2m | 1.5m | 3.8m | 3.9m | 4.1m | 2.8m | 1.4m | 715.0k |

## R&D expense | 20.4m | 27.1m | 24.1m | 26.2m | 26.5m | 24.7m | 27.4m | 25.7m | 25.0m | 25.8m | 25.0m | 21.9m | 21.9m | 21.4m | 11.2m | 10.1m |

## General and administrative expense | 3.6m | 4.6m | 4.8m | 5.0m | 8.2m | 8.5m | 9.3m | 7.8m | 7.0m | 7.2m | 6.5m | 5.3m | 5.6m | 5.6m | 4.9m | 3.9m |

## Operating expense total | 24.2m | 31.9m | 29.1m | 31.4m | 34.9m | 33.4m | 37.0m | 33.8m | 32.2m | 36.6m | 32.8m | 35.9m | 123.7m | 19.6m | 19.4m | 13.0m |

## EBIT | (23.3m) | (31.5m) | (28.5m) | (30.3m) | (32.7m) | (32.4m) | (35.7m) | (32.4m) | (30.0m) | (35.1m) | (28.9m) | (32.0m) | (119.7m) | (16.9m) | (17.9m) | (12.3m) |

| (2374%) | (7569%) | (4822%) | (2756%) | (1504%) | (3155%) | (2740%) | (2330%) | (1351%) | (2289%) | (755%) | (815%) | (2942%) | (611%) | (1259%) | (1714%) |

## Interest expense | 13.0k | |||||||||||||||

## Income tax expense | 5.2m | 765.0k | 765.0k | |||||||||||||

## Net Income | (23.1m) | (29.9m) | (28.3m) | (28.1m) | (32.4m) | (32.0m) | (34.7m) | (32.0m) | (29.6m) | (34.3m) | (28.6m) | (26.4m) | (118.1m) | (16.4m) | (17.2m) | (11.8m) |

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 169.4m | 28.0m | 72.1m | 42.5m | 40.3m | 24.3m |

## Accounts Receivable | 489.0k | 427.0k | 97.0k | 1.8m | ||

## Current Assets | 305.2m | 205.0m | 294.9m | 195.6m | 144.8m | 99.1m |

## PP&E | 10.0m | 10.5m | 11.5m | 13.2m | 10.4m | 6.1m |

## Goodwill | 9.0m | 9.0m | 9.0m | 91.0m | 91.0m | |

## Total Assets | 347.1m | 248.0m | 337.6m | 383.4m | 315.6m | 155.8m |

## Accounts Payable | 2.2m | 2.6m | 1.5m | 1.7m | 1.7m | 1.1m |

## Current Liabilities | 20.4m | 24.5m | 30.2m | 35.2m | 27.7m | 12.6m |

## Total Liabilities | 27.3m | 47.5m | 117.9m | 79.3m | 31.7m | |

## Additional Paid-in Capital | 662.7m | 672.7m | 878.7m | 982.3m | 1.0b | 1.1b |

## Retained Earnings | (345.7m) | (463.8m) | (591.0m) | (719.5m) | (812.5m) | (962.4m) |

## Total Equity | 319.8m | 211.7m | 290.1m | 265.4m | 236.4m | 124.1m |

## Financial Leverage | 1.1 x | 1.2 x | 1.2 x | 1.4 x | 1.3 x | 1.3 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (81.5m) | (118.1m) | (127.2m) | (128.5m) | (93.0m) | (151.2m) |

## Depreciation and Amortization | 1.9m | 2.4m | 3.0m | 3.1m | 4.4m | 3.6m |

## Accounts Payable | 7.2m | 1.5m | 4.9m | (5.0m) | (8.7m) | (13.1m) |

## Cash From Operating Activities | (67.7m) | (101.5m) | (98.9m) | (113.0m) | (99.9m) | (75.2m) |

## Purchases of PP&E | (4.2m) | (1.9m) | (4.9m) | (2.8m) | (1.8m) | (813.0k) |

## Cash From Investing Activities | (77.4m) | (41.0m) | (50.2m) | 68.9m | 46.5m | 29.8m |

## Cash From Financing Activities | 289.6m | 1.2m | 193.2m | 14.5m | 51.3m | 29.4m |

## Interest Paid | 1.2m | 1.2m | 1.2m |

- Source: SEC Filings

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (59.5m) | (29.9m) | (58.2m) | (86.3m) | (32.4m) | (32.0m) | (34.7m) | (32.0m) | (29.6m) | (34.3m) | (62.8m) | (89.2m) | (118.1m) | (134.5m) | (17.2m) | (29.0m) | |

## Depreciation and Amortization | 1.4m | 579.0k | 1.2m | 1.8m | 1.4m | 2.4m | 3.4m | 1.0m | 2.0m | 1.4m | 2.5m | ||||||

## Accounts Payable | 3.0m | (1.7m) | (1.0m) | (740.0k) | 3.1m | 2.0m | 1.2m | 2.6m | 706.0k | 1.0m | (8.3m) | (6.8m) | (10.9m) | (5.9m) | (5.9m) | (1.5m) | (1.6m) |

## Cash From Operating Activities | (52.7m) | (31.9m) | (52.7m) | (79.3m) | (35.3m) | (56.0m) | (80.4m) | (28.0m) | (45.4m) | (13.2m) | (24.3m) | ||||||

## Purchases of PP&E | (1.9m) | (195.0k) | (1.1m) | (1.8m) | (374.0k) | (1.3m) | (1.6m) | (259.0k) | (591.0k) | (186.0k) | (484.0k) | ||||||

## Cash From Investing Activities | (63.6m) | (81.3m) | (76.7m) | (58.7m) | 22.4m | 58.2m | 59.9m | 15.5m | 28.7m | 16.3m | 8.3m | ||||||

## Cash From Financing Activities | 106.0m | 702.0k | 856.0k | 1.2m | 12.9m | 21.6m | 32.8m | 12.1m | 20.3m | 4.2m | 11.4m |

- Source: SEC Filings

USD | Y, 2019 |
---|---|

## EV/EBIT | -1.5 x |

## EV/CFO | -0.8 x |

## Financial Leverage | 1.3 x |